Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATURATION trial of local APAC to improve arteriovenous fistula maturation in end stage kidney disease
2026-526207-30-00Phase 2Authorised
- Sponsor
- Aplagon
- Start
- Sep 2026
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of APAC in chronic kidney disease (CKD) (3 arms), sponsored by Aplagon. Primary endpoints: Safety and tolerability, Local signs and symptoms at AVF site and 7 more. Planned start Sep 2026; status: authorised.
02
Drugs
APAC
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2026-526207-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526207-30-00.